Scientists have found that learning and memory formation decline in Alzheimer’s disease can be improved by the Triple drug created to treat Diabetes. Alzheimer’s disease is a chronic neurodegenerative disorder leading to 60%-70% of cases of Dementia. The disease includes problems with language, disorientation, mood swings, loss of motivation, inability to manage self care, and behavioral issues.
The report published in the Journal Brain shows neuroprotective effects of triple receptor agonist (TA). The Triple Agents have shown to activate GIP-1, GIP and glucagon receptors at the same time in patients with Alzheimer’s Disease. The triple agents Type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer disease (AD) and the Triple Agents had shown promising effects in animal models of Diabetes Mellitus.
Researchers from Alzheimer Society UK aiming to evaluate the efficacy of Triple Agents in reduction of amount of beta-amyloid, neuroinflammation and oxidative stress, injected Triple Agents twice daily in APP/PS1 mice, which are transgenic mice that express human mutated genes that cause Alzheimer’s.
The results of Research were quite influencing with significant reduction in beta-amyloid, neuroinflammation and oxidative stress in Transgenic mice with expressed mutated genes to cause Alzheimer’s disease. The major results of Triple Agents treatment in the study was summarized in 8 points:
1.Improvement of learning and memory impairment (Reversal of Memory Loss)
2.TA-treatment ameliorated amyloid plaques in the brains.
3. Reduced chronic inflammation response in the cortex and hippocampus.
4.Suppressed oxidative stress in the cortex and hippocampus.
5. Increased immature neurons in the dentate gyrus.
6. Reversed the decrease of BDNF levels in the hippocampus.
7. Reversed the reduction of synaptophysin levels
8. Potential anti-apoptotic effects by decreasing the BAX/Bcl-2 ratio
These results obtained in Transgenic mutated mouse model show that Triple Agents could be novel candidates for future treatment trails in Alzheimer’s Disease.
Lin Li et al. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer’s disease, 2018. Brain Res.1;1678:64-74